Clinical trial · Interventional
Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma
NCT01151748CI-TRIAL-00006896withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study abandoned; Could not obtain final SRC approval due to IND disagreements
Summary
Brief summary (as posted)
Phase II study of selective intra-arterial infusion of chemotherapy for intraocular retinoblastoma
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Eye Cancer | Malignant Eye Neoplasm | ALIAS | 0.90 |
| Retinoblastoma | Retinoblastoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intra-arterial infusion of chemotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response: Globe salvage rate (Eyes saved/Eyes treated). This will be determined by clinical ocular examination.
- timeFrame
- Follow-up will be performed for one year from treatment date.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients diagnosed with advanced intraocular retinoblastoma (International Retinoblastoma Classification group D or E\*). 2. Patients with tumor recurrence or vitreous seeding following completion of systemic chemotherapy or previous radiation therapy. Exclusion Criteria: 1. Congenital brain anomaly identified on MRI. 2. History of systemic coagulopathy. 3. Evidence of extra ocular retinoblastoma on clinical examination or neuroimaging.
References
Publications (0)
Data not yet available
No reference posted for this study.